ClinicalTrials.gg
TerminatedNCT03979508Updated Nov 2, 2026Results posted

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

A Phase 2 interventional study of Abemaciclib and Therapeutic Conventional Surgery in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage III Breast Cancer AJCC v8, sponsored by Mayo Clinic. Terminated at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Why this study was terminated
The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in first stage of study.
Updated Nov 2, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Enrollment
127th of 171
26 · median 51
Started
2020
with 9 others
Phase 2
60 of 210
9 open now
Registered
162nd of 210
by date
Lead sponsor
8 of 210
Mayo Clinic

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 127th largest by enrollment of the 171 interventional ones that give a count, is one of 10 that started in 2020, is one of 60 in phase 2, and was the 162nd registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy alone, or in combination with pembrolizumab. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Read the detailed description

PRIMARY OBJECTIVE:

I. To examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy resistant triple negative breast cancer (TNBC) patients following neoadjuvant chemotherapy regimen without the addition of pembrolizumab (Cohort A).

II. To examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy resistant TNBC patients following a neoadjuvant chemotherapy regimen with the addition of pembrolizumab (Cohort B).

SECONDARY OBJECTIVES for Cohort A and Cohort B Independently:

I. Assess abemaciclib toxicities. II. To examine the effects of abemaciclib on the percentage of vimentin expressing invasive cancer cells

III. Within TNBC molecular subtypes (basal, mesenchymal, and luminal androgen receptor [LAR]), to evaluate the effects of abemaciclib on:

IIIa. The individual elements of tumor grade (mitoses, nuclear pleomorphism, and tubule formation).

IIIb. Tumor proliferation (as measured by tumor Ki-67 and serum tyrosine kinase inhibitor [TKI]).

IIIc. pDUB3 as well as epithelial-mesenchymal transition (EMT) markers including SNAIL/SLUG, TWIST, and E-Cadherin as measured by immunohistochemistry (IHC).

IIId. Quantification of tumor-infiltrating lymphocytes (as examined by hematoxylin and eosin [H\&E]).

EXPLORATORY OBJECTIVES for Cohort A and Cohort B Independently:

I. To evaluate the effect of abemaciclib on tumor ribonucleic acid (RNA) expression.

II. To evaluate the effects of abemaciclib on the immune phenotype of peripheral blood mononuclear cells (PBMC), by evaluating expression of a panel of cell surface markers optimized of identification of human immune cell subpopulations.

III. To evaluate the effects of abemaciclib on tumor-infiltrating immune cells in formalin-fixed paraffin-embedded (FFPE) tumor sections, using multiplexed imaging technologies (e.g imaging mass cytometry, Nanostring digital spatial profiling [DSP] or CODEX) which will include:

IIIa. Genes directly involved in tumor cell antigen presentation (e.g. B2M, HLA-A, HLA-B, HLA-C, TAP1, TAP2, TAPBP).

IIIb. Interferon-stimulated genes (ISGs) that regulate antigen presentation (e.g. STAT1, NLRC5) and other ISGs (e.g. IRFs, OAS2).

IIIc. Genes involved in double-strand ribonucleic acid (dsRNA) response (e.g. DDX58, DHX58).

IIId. Genes encoding interferons, including type 3 IFNs (e.g. IFNL1, IFNL2, IFNL3).

IIIe. Genes indicating a cytotoxic T cell response (e.g. PRF1, GZMB). IIIf. Regulatory T-cell (Treg)-specific transcription factor genes (e.g. FOXP3, IKZF2).

IV. To assess the difference in the frequency of JAK-2 amplification among patients whose post-abemaciclib CD8/FOXP3 ratio >= 1.6 and that among patients whose post-abemaciclib CD8/FOXP3 ratio \< 1.6.

V. To generate organoids for future research. VI. To evaluate changes in the microbiome with exposure to abemaciclib.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT A: Patients receive a neoadjuvant chemotherapy regimen without pembrolizumab.

GROUP 1: Patients undergo standard of care surgical resection.

GROUP 2: Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.

After completion of study treatment, patients in group 2 are followed up within 30-60 days.

COHORT B: Patients receive a neoadjuvant chemotherapy regimen in combination with pembrolizumab.

GROUP 3: Patients undergo standard of care surgical resection.

GROUP 4: Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.

After completion of study treatment, patients in group 4 are followed up within 30-60 days.

03

Conditions studied

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Breast Ductal Carcinoma In Situ
  • Breast Fibrocystic Change
  • Breast Lobular Carcinoma In Situ
  • Invasive Breast Carcinoma
  • Prognostic Stage I Breast Cancer AJCC v8
  • Prognostic Stage IA Breast Cancer AJCC v8
  • Prognostic Stage IB Breast Cancer AJCC v8
  • Prognostic Stage II Breast Cancer AJCC v8
  • Prognostic Stage IIA Breast Cancer AJCC v8
  • Prognostic Stage IIB Breast Cancer AJCC v8
  • Prognostic Stage III Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Triple-Negative Breast Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of age >=18 years
  • PRE-REGISTRATION: Clinical T1-4, N0-3, M0 breast cancer at diagnosis (prior to the start of chemotherapy) by American Joint Committee on Cancer (AJCC) staging version 8.

    • Note: Benign breast disease, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS) in the ipsilateral or contralateral breast is allowed.
    • Note: Additional ipsilateral or contralateral invasive breast cancer is allowed. The index lesion is the largest triple-negative, chemotherapy-resistant lesion.
  • PRE-REGISTRATION: Histological confirmation of triple negative invasive breast cancer (defined as estrogen receptor [ER] =\< 10%, progesterone receptor [PR] =\< 10% and not amplified by in situ hybridization [ISH] or immunohistochemistry [IHC] 0/1) at diagnosis.
  • PRE-REGISTRATION: Cohort A: CLOSED TO PRE-REGISTRATION and REGISTRATION as of protocol amendment 6 (04/14/2023) Neoadjuvant chemotherapy (NAC) with one of the following regimens that was not discontinued early due to intolerability with less than 50% of planned treatment given due to disease progression or patient request:

    • Paclitaxel or docetaxel followed by one of the following: the combination of doxorubicin and cyclophosphamide (AC); the combination of epirubicin and cyclophosphamide (EC) or the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC)

      • Note: Carboplatin may be added to these regimens
    • AC or EC or FEC followed by docetaxel or paclitaxel

      • Note: Carboplatin may be added to these regimens
    • Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
    • Docetaxel in combination with cyclophosphamide (TC) (for patients who are not candidates for anthracyclines)
    • Carboplatin or cisplatin in combination with a taxane (paclitaxel, docetaxel, or nab-paclitaxel) (for patients who are not candidates for anthracyclines)
  • PRE-REGISTRATION: Cohort B: Neoadjuvant chemotherapy (NAC) with one of the following regimens in combination with pembrolizumab that was not discontinued early due to intolerability with less than 50% of planned treatment given due to disease progression or patient request:

    • Paclitaxel or docetaxel followed by one of the following: the combination of doxorubicin and cyclophosphamide (AC); the combination of epirubicin and cyclophosphamide (EC) or the combination of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) Note: Carboplatin may be added to these regimens
    • AC or EC or FEC followed by docetaxel or paclitaxel [Note: Carboplatin may be added to these regimens]
    • Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
    • Docetaxel in combination with cyclophosphamide (TC)
    • Carboplatin or cisplatin in combination with a taxane (paclitaxel, docetaxel, or nab-paclitaxel)
  • PRE-REGISTRATION: Residual lesion/enhancement seen in the breast on breast imaging performed after completion of NAC.
  • PRE-REGISTRATION: Able to swallow oral medication.
  • PRE-REGISTRATION: Willing to undergo for research.
  • PRE-REGISTRATION: Willing to provide tissue and blood samples for correlative research purposes.
  • PRE-REGISTRATION: Willing to stop use of strong and moderate inducers and/or strong inhibitors of cytochrome P450 3A =\< 7 days prior to registration.
  • PRE-REGISTRATION: Provide written .
  • REGISTRATION: Registration must occur =\< 56 days after last dose of NAC.
  • REGISTRATION: (ECOG) performance status (PS) 0, 1, or 2.
  • REGISTRATION: COHORT B GROUP 4 ONLY: The following laboratory values obtained after completion of NAC but =\< 14 days prior to registration:
  • REGISTRATION: COHORT B GROUP 4 ONLY: (ANC) >= 1500/mm\^3.
  • REGISTRATION: COHORT B GROUP 4 ONLY: (PLT) >= 100,000/mm\^3.
  • REGISTRATION: COHORT B GROUP 4 ONLY: (HgB) >= 8.0 g/dL.
  • REGISTRATION: COHORT B GROUP 4 ONLY: Total =\< 1.5 x (ULN).
  • REGISTRATION: COHORT B GROUP 4 ONLY: (AST) serum glutamic oxaloacetic transaminase (SGOT) =\< 3 x ULN.
  • REGISTRATION: COHORT B GROUP 4 ONLY: Alanine transaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =\< 3 x ULN.
  • REGISTRATION: COHORT B GROUP 4 ONLY: Serum creatinine =\< 1.5 x ULN.
  • REGISTRATION: GROUP 2 ONLY: Negative pregnancy test done =\< 7 days prior to registration, for persons of only.

Exclusion criteria

Exclusion Criteria:

  • PRE-REGISTRATION: History of deep venous thrombosis (DVT) or pulmonary embolisms (PE) =\< 12 months prior to preregistration; OR Active DVT and/or PE requiring anti-coagulant therapy.

    • NOTE: Patients who are on anti-coagulant therapy for maintenance are eligible as long as the DVT and/or PE was > 12 months prior to enrollment and there is no evidence for active thrombosis (either DVT or PE).
    • NOTE: Patients on anticoagulation are eligible; however peri- and peri-surgical management of anticoagulation is per the institutional standard of care.
  • PRE-REGISTRATION: Prior treatment with CDK 4/6 inhibitors (e.g. palbociclib, ribociclib, abemaciclib, etc.)
  • PRE-REGISTRATION: Prior treatment with radiation for this breast cancer.
  • PRE-REGISTRATION: Prior incisional or excisional breast biopsy for this cancer.
  • PRE-REGISTRATION: Any to pre-registration biopsy (such as bleeding diatheses, etc.).
  • PRE-REGISTRATION: Receiving any agent which would be considered as a treatment for the primary neoplasm.
  • PRE-REGISTRATION: Other active =\< 3 years prior to registration.

    • EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.
    • NOTE: If there is a history of prior malignancy, they must not be receiving another specific treatment for prior malignancy.
  • PRE-REGISTRATION: Biopsy proven Stage IV breast cancer.
  • PRE-REGISTRATION: Serious pre-existing medical conditions that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g., estimated \< 30 ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea).
  • PRE-REGISTRATION: History of any of the following conditions:

    • Syncope of cardiovascular etiology.
    • Ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation).
    • Sudden cardiac arrest.
    • NOTE: Patients on anticoagulation are eligible; however peri-biopsy and peri-surgical management of anticoagulation is per the institutional standard of care.
  • REGISTRATION: COHORT B GROUP 4: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:

    • Pregnant persons.
    • Nursing persons.
    • Persons of who are unwilling to employ adequate .
  • REGISTRATION: COHORT B GROUP 4: Failure to recover to grade 1 or lower from effects of chemotherapy.

    • Exceptions: Residual alopecia and grade 2 peripheral neuropathy are allowed.
  • REGISTRATION: COHORT B GROUP 4: Concurrent use of strong and moderate inducers and/or strong inhibitors of cytochrome P450 3A =\< 7 days prior to registration.
  • REGISTRATION: COHORT B GROUP 4: Known infections as follows (NOTE: Screening is not required for enrollment):

    • Active systemic bacterial infection requiring intravenous antibiotics.
    • Active fungal infection (requiring intravenous or oral antifungal treatment).
    • Detectable viral infections (e.g. known [HIV], known active or C).
  • REGISTRATION: COHORT B GROUP 4: Concurrent use of chemotherapy, radiotherapy, immunotherapy, or other components of neoadjuvant treatment.

    • NOTE: Patients must complete all elements of NAC ≥21 days prior to starting abemaciclib.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort A Group 1; Cohort B Group 3 (surgery)

    Patients undergo standard of care surgical resection.

    Procedure: Therapeutic Conventional Surgery

  • Experimental
    Cohort A Group 2; Cohort B Group 4 (abemaciclib, surgery)

    Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.

    Drug: Abemaciclib · Procedure: Therapeutic Conventional Surgery

Interventions

  • Given PO

    Also known as: LY-2835219, LY2835219, Verzenio

  • ProcedureTherapeutic Conventional Surgery

    Undergo standard of care surgical resection

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Have a CD8/FOXP3 Ratio < 1.6 in Their Residual Tumors After Neoadjuvant Chemotherapy (NAC) That Convert to CD8/FOXP3 Ratio >= 1.6

    A Simon optimum two stage phase II clinical trial design was chosen to test the null hypothesis that the rate of conversion to post-abemaciclib CD8/FOXP3 ratio of 1.6 or more is =\< 5% against the alternative that rate of conversion to post-abemaciclib CD8/FOXP3 ratio of 1.6 or more is \>= 20% with the target probability of a type I error and probability of a type II error set to 0.10. The probability of terminating after the first stage is 0.736, if the null hypothesis is true. A 90% confidence interval for this rate of conversion will be constructed using the Duffy-Santner approach taking into account the sequential nature of the study

    Time frame: 21 days

Secondary outcomes

  1. Number of Patients Experiencing a Grade 3 or Greater of Adverse Event

    Adverse events will be monitored and graded with attribution assigned using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number of patients experiencing a grade 3 or greater AE will be reported

    Time frame: 60 days

  2. Changes in Vimentin Expression

    Vimentin expression will be evaluated by immunohistochemistry (IHC) with using 0, 1+, 2+ or 3+ scoring scheme. A point estimate of the proportion of eligible patients whose post-NAC residual tumor Vimentin expression levels were 2+ or 3+ and then fell to 0 or 1+ after abemaciclib among the eligible patients whose began abemaciclib treatment after a post NAC residual tumor Vimentin expression level finding of 2+ or 3+ will be calculated. A 90% confidence interval for this proportion will be constructed using one-sample binomial confidence for proportions.

    Time frame: 60 days

  3. Impact of Length of Treatment

    Association between amount of abemaciclib received and the change in CD8/FOXP3 ratio after abemaciclib will be explored graphically. A plot of the change in change in CD8/FOXP3 ratio after abemaciclib and days of treatment will be constructed to visually assess for trends. Also, the a 90% confidence interval for the difference in binomial proportions will be constructed to assess whether the proportion of patients whose post abemaciclib CD8/FOXP3 ratio \>= 1.6 after completing 14-21 days of abemaciclib differs between those who discontinued abemaciclib the day prior to surgery and who discontinued abemaciclib 2 or more days prior to surgery. CD8/FOXP3 protein expression will be determined in tumor tissue obtained in residual invasive breast cancer obtained at surgery. Tissue samples will be frozen and processed centrally separate from the patient's progression through the study.

    Time frame: 60 days

Other outcomes

  1. Changes in Mitoses

    Examined graphically overall and by triple negative breast cancer (TNBC) subtypes.

    Time frame: Up to 60 days

  2. Changes in Nuclear Pleomorphism

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  3. Changes in Tubule Formation

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  4. Changes in Tumor Ki-67

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  5. Changes in Serum Tyrosine Kinase Inhibitor (TKI)

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  6. Changes in SNAIL

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  7. Changes in SLUG

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  8. Changes in E-Cadherin

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  9. Changes in Tumor-infiltrating Lymphocytes

    Examined graphically overall and by TNBC subtypes.

    Time frame: Up to 60 days

  10. Effect of Abemaciclib on Tumor Ribonucleic Acid (RNA)-Sequencing (Seq) Data

    Effect of abemaciclib on tumor RNA sequencing followed by standard and\> customized pathway and enrichment analysis (e.g., Gene set enrichment\> analysis (GSEA) and CIBERSORT methods). The GSEA method determines whether an a priori set of genes are over-represented in the differential expression analysis of the pre- and post- drug response phenotypes. Similarly, CIBERSORT estimates cell composition from RNA transcriptomic data (e.g. immune cell populations).

    Time frame: Up to 60 days

  11. Effect of Abemaciclib on the Phenotype of Peripheral Blood Mononuclear Cells (PBMC)

    Will be assessed using mass cytometry (e.g,. CyTOF) to analyze a panel of 29 cell surface markers optimized for identification of human immune cell subsets, including the following targets: CD45, CD195 (CCR6), CD19, CD127, CD38, IgD, CD11c, CD16, CD194 (CCR4), CD123/IL-3R, TCRgd, CD185 (CXCR5), CD3, CD45RA, CD27, CD29, CD66b, CD183 (CXCR3), CD161, CD45RO, CD197 (CCR7), CD8a, CD25/IL-2R, CD20, HLA-DR, CD4, CD14, CD56/NCAM. Identification of specific immune cell subsets will be assessed using consensus clustering methods of predefined combination of markers.

    Time frame: Up to 60 days

  12. Effect of Abemaciclib on Formalin-fixed Paraffin-embedded (FFPE) Tumor Sections

    Will include (imaging mass cytometry multiplex quantitative RNA/protein immune-based profilings, such as Hyperion TM, Nanostring GeoMX, Codex, and may include the examination of genes directly involved in tumor cell antigen presentation (e.g. B2M, HLA-A, HLA-B, HLA-C, TAP1, TAP2, TAPBP), interferon-stimulated genes (ISGs) that regulate antigen presentation (e.g. STAT1, NLRC5) and other ISGs (e.g. IRFs, OAS2), genes involved in double strand RNA response (e.g. DDX58, DHX58), genes encoding interferons, including type 3 IFNs (e.g. IFNL1, IFNL2, IFNL3), genes indicating a cytotoxic T cell response (e.g. PRF1, GZMB), regulatory T cell-specific transcription factor genes (e.g., FOXP3, IKZF2)

    Time frame: Up to 60 days

  13. Change in in Frequency of JAK-2 Amplifications

    The collection of JAK-2 will be used to assess the difference in the frequency of JAK-2 amplification among patients whose post-abemaciclib CD8/FOXP3 ratio \>= 1.6 and that among patients whose post-abemaciclib CD8/FOXP3 ratio \< 1.6. A 95% binomial confidence for the difference in two independent proportions will be constructed for the difference in the percentage of patients with a post-abemaciclib CD8/FOXP3 ratio \>= 1.6 among those with JAK-2 amplified TNBC and those with JAK-2 non-amplified TNBC.

    Time frame: Baseline up to time of surgery

  14. Change in Microbiome With Exposure to Abemaciclib

    The collection of microbiome information via stool collection will be used to generate descriptive analyses about the study population, as the total number of samples is expected to be insufficient for full statistical analysis. Will explore putative mechanistic connections underlying bacteria-drug interactions in all patients and attempt to identify the biomolecular features within the gut (stool) microbiome and its association with the pharmacokinetics and pharmacodynamics of abemaciclib.

    Time frame: Baseline up to prior to surgery

07

Results

Posted Nov 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2
Started1015
Completed1015
Not completed00

Outcome measures

PrimaryNumber of Patients Who Have a CD8/FOXP3 Ratio < 1.6 in Their Residual Tumors After Neoadjuvant Chemotherapy (NAC) That Convert to CD8/FOXP3 Ratio >= 1.6

A Simon optimum two stage phase II clinical trial design was chosen to test the null hypothesis that the rate of conversion to post-abemaciclib CD8/FOXP3 ratio of 1.6 or more is =\< 5% against the alternative that rate of conversion to post-abemaciclib CD8/FOXP3 ratio of 1.6 or more is \>= 20% with the target probability of a type I error and probability of a type II error set to 0.10. The probability of terminating after the first stage is 0.736, if the null hypothesis is true. A 90% confidence interval for this rate of conversion will be constructed using the Duffy-Santner approach taking into account the sequential nature of the study

Time frame:
21 days
Reported as:
Count of participants · Participants
Number of Patients Who Have a CD8/FOXP3 Ratio < 1.6 in Their Residual Tumors After Neoadjuvant Chemotherapy (NAC) That Convert to CD8/FOXP3 Ratio >= 1.6
ParticipantsGroup 1Group 2
Number of Patients Who Have a CD8/FOXP3 Ratio < 1.6 in Their Residual Tumors After Neoadjuvant Chemotherapy (NAC) That Convert to CD8/FOXP3 Ratio >= 1.600
SecondaryNumber of Patients Experiencing a Grade 3 or Greater of Adverse Event

Adverse events will be monitored and graded with attribution assigned using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number of patients experiencing a grade 3 or greater AE will be reported

Time frame:
60 days
Reported as:
Count of participants · Participants
Number of Patients Experiencing a Grade 3 or Greater of Adverse Event
ParticipantsGroup 1Group 2
Number of Patients Experiencing a Grade 3 or Greater of Adverse Event04
SecondaryChanges in Vimentin Expression

Vimentin expression will be evaluated by immunohistochemistry (IHC) with using 0, 1+, 2+ or 3+ scoring scheme. A point estimate of the proportion of eligible patients whose post-NAC residual tumor Vimentin expression levels were 2+ or 3+ and then fell to 0 or 1+ after abemaciclib among the eligible patients whose began abemaciclib treatment after a post NAC residual tumor Vimentin expression level finding of 2+ or 3+ will be calculated. A 90% confidence interval for this proportion will be constructed using one-sample binomial confidence for proportions.

Time frame:
60 days
Reported as:
Count of participants · Participants
Changes in Vimentin Expression
ParticipantsGroup 1Group 2
Decrease03
No decrease07
Insufficient tissue05
SecondaryImpact of Length of Treatment

Association between amount of abemaciclib received and the change in CD8/FOXP3 ratio after abemaciclib will be explored graphically. A plot of the change in change in CD8/FOXP3 ratio after abemaciclib and days of treatment will be constructed to visually assess for trends. Also, the a 90% confidence interval for the difference in binomial proportions will be constructed to assess whether the proportion of patients whose post abemaciclib CD8/FOXP3 ratio \>= 1.6 after completing 14-21 days of abemaciclib differs between those who discontinued abemaciclib the day prior to surgery and who discontinued abemaciclib 2 or more days prior to surgery. CD8/FOXP3 protein expression will be determined in tumor tissue obtained in residual invasive breast cancer obtained at surgery. Tissue samples will be frozen and processed centrally separate from the patient's progression through the study.

Time frame:
60 days

No measurements were reported for this outcome.

Other pre-specifiedChanges in Mitoses

Examined graphically overall and by triple negative breast cancer (TNBC) subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Nuclear Pleomorphism

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Tubule Formation

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Tumor Ki-67

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Serum Tyrosine Kinase Inhibitor (TKI)

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in SNAIL

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in SLUG

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in E-Cadherin

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChanges in Tumor-infiltrating Lymphocytes

Examined graphically overall and by TNBC subtypes.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedEffect of Abemaciclib on Tumor Ribonucleic Acid (RNA)-Sequencing (Seq) Data

Effect of abemaciclib on tumor RNA sequencing followed by standard and\> customized pathway and enrichment analysis (e.g., Gene set enrichment\> analysis (GSEA) and CIBERSORT methods). The GSEA method determines whether an a priori set of genes are over-represented in the differential expression analysis of the pre- and post- drug response phenotypes. Similarly, CIBERSORT estimates cell composition from RNA transcriptomic data (e.g. immune cell populations).

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedEffect of Abemaciclib on the Phenotype of Peripheral Blood Mononuclear Cells (PBMC)

Will be assessed using mass cytometry (e.g,. CyTOF) to analyze a panel of 29 cell surface markers optimized for identification of human immune cell subsets, including the following targets: CD45, CD195 (CCR6), CD19, CD127, CD38, IgD, CD11c, CD16, CD194 (CCR4), CD123/IL-3R, TCRgd, CD185 (CXCR5), CD3, CD45RA, CD27, CD29, CD66b, CD183 (CXCR3), CD161, CD45RO, CD197 (CCR7), CD8a, CD25/IL-2R, CD20, HLA-DR, CD4, CD14, CD56/NCAM. Identification of specific immune cell subsets will be assessed using consensus clustering methods of predefined combination of markers.

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedEffect of Abemaciclib on Formalin-fixed Paraffin-embedded (FFPE) Tumor Sections

Will include (imaging mass cytometry multiplex quantitative RNA/protein immune-based profilings, such as Hyperion TM, Nanostring GeoMX, Codex, and may include the examination of genes directly involved in tumor cell antigen presentation (e.g. B2M, HLA-A, HLA-B, HLA-C, TAP1, TAP2, TAPBP), interferon-stimulated genes (ISGs) that regulate antigen presentation (e.g. STAT1, NLRC5) and other ISGs (e.g. IRFs, OAS2), genes involved in double strand RNA response (e.g. DDX58, DHX58), genes encoding interferons, including type 3 IFNs (e.g. IFNL1, IFNL2, IFNL3), genes indicating a cytotoxic T cell response (e.g. PRF1, GZMB), regulatory T cell-specific transcription factor genes (e.g., FOXP3, IKZF2)

Time frame:
Up to 60 days

Results for this outcome have not been posted.

Other pre-specifiedChange in in Frequency of JAK-2 Amplifications

The collection of JAK-2 will be used to assess the difference in the frequency of JAK-2 amplification among patients whose post-abemaciclib CD8/FOXP3 ratio \>= 1.6 and that among patients whose post-abemaciclib CD8/FOXP3 ratio \< 1.6. A 95% binomial confidence for the difference in two independent proportions will be constructed for the difference in the percentage of patients with a post-abemaciclib CD8/FOXP3 ratio \>= 1.6 among those with JAK-2 amplified TNBC and those with JAK-2 non-amplified TNBC.

Time frame:
Baseline up to time of surgery

Results for this outcome have not been posted.

Other pre-specifiedChange in Microbiome With Exposure to Abemaciclib

The collection of microbiome information via stool collection will be used to generate descriptive analyses about the study population, as the total number of samples is expected to be insufficient for full statistical analysis. Will explore putative mechanistic connections underlying bacteria-drug interactions in all patients and attempt to identify the biomolecular features within the gut (stool) microbiome and its association with the pharmacokinetics and pharmacodynamics of abemaciclib.

Time frame:
Baseline up to prior to surgery

Results for this outcome have not been posted.

Adverse events

Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 10/10 (0%)——
Group 20/15 (0%)1/15 (6.7%)13/15 (86.7%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2
Wound infectionInfections and infestations—1/15
Most frequent other events
Showing 10 of 29
Most frequent other events
EventGroup 1Group 2
AnemiaBlood and lymphatic system disorders—10/15
DiarrheaGastrointestinal disorders—10/15
NauseaGastrointestinal disorders—9/15
Platelet count decreasedInvestigations—9/15
FatigueGeneral disorders—4/15
Lymphocyte count decreasedInvestigations—3/15
VomitingGastrointestinal disorders—2/15
Alanine aminotransferase increasedInvestigations—2/15
Neutrophil count decreasedInvestigations—2/15
AnorexiaMetabolism and nutrition disorders—2/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1Group 2Total
Median47 (31 to 64)59 (30 to 74)53 (30 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Total
Female101525
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1Group 2Total
Hispanic or Latino202
Not Hispanic or Latino81523
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1Group 2Total
American Indian or Alaska Native101
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American000
White81321
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Group 1Group 2Total
United States101525
BMI Group
BMI Group(Participants)Group 1Group 2Total
Underweight/Normal156
Overweight/Obese91019
Menopausal status
Menopausal status(Participants)Group 1Group 2Total
Premenopausal459
Postmenopausal51015
Unknown101
CD8/FOXP3 Ratio
CD8/FOXP3 Ratio(Participants)Group 1Group 2Total
< 1.6011
>= 1.6099
Insufficient tissue055
08

Study locations

3 sites
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224-9980, United States
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Dec 2024, 59 months.

Results were first posted in Nov 2026, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jun 7, 2019
StartActual
Jan 10, 2020
Primary completionActual
Dec 26, 2024
CompletionActual
Dec 26, 2024
Results first posted
Nov 2, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportionNumber of patients who havePatients Who Have a CD8/FOXP3 ratioRatio < 1.6 in their residual tumors after neoadjuvant chemotherapyTheir Residual Tumors After Neoadjuvant Chemotherapy (NAC) that convertThat Convert to CD8/FOXP3 ratioRatio >= 1.6Time frame: Up to 21 days → 21 days
Nov 2, 2026
Documents
Secondary outcomes
14 edited
What changed in the outcomes
  • EditedChanges in vimentin expressionVimentin ExpressionTime frame: Up to 60 days → 60 days
  • EditedImpact of lengthLength of treatmentTreatmentTime frame: Up to 60 days → 60 days
  • ChangedBefore Incidence of adverse eventsNow Number of Patients Experiencing a Grade 3 or Greater of Adverse EventTime frame: Up to 60 days → 60 days
  • Editedother outcomeChanges in mitosesMitosesTime frame: Up to 60 days
  • Editedother outcomeChanges in nuclear pleomorphismNuclear PleomorphismTime frame: Up to 60 days
  • Editedother outcomeChanges in tubule formationTubule FormationTime frame: Up to 60 days
  • Editedother outcomeChanges in tumorTumor Ki-67Time frame: Up to 60 days
  • Editedother outcomeChanges in serum tyrosine kinase inhibitorSerum Tyrosine Kinase Inhibitor (TKI)Time frame: Up to 60 days
  • Editedother outcomeChanges in tumorTumor-infiltrating lymphocytesLymphocytesTime frame: Up to 60 days
  • Editedother outcomeEffect of abemaciclibAbemaciclib on tumor ribonucleic acidTumor Ribonucleic Acid (RNA)-sequencingSequencing (seqSeq) dataDataTime frame: Up to 60 days
  • Editedother outcomeEffect of abemaciclibAbemaciclib on the phenotypePhenotype of peripheral blood mononuclear cellsPeripheral Blood Mononuclear Cells (PBMC)Time frame: Up to 60 days
  • Editedother outcomeEffect of abemaciclibAbemaciclib on formalinFormalin-fixed paraffinParaffin-embedded (FFPE) tumor sectionsTumor SectionsTime frame: Up to 60 days
  • Editedother outcomeChange in in frequencyFrequency of JAK-2 amplificationsAmplificationsTime frame: Baseline up to time of surgery
  • Editedother outcomeChange in microbiome with exposureMicrobiome With Exposure to abemaciclibAbemaciclibTime frame: Baseline up to prior to surgery
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportionNumber of patients who havePatients Who Have a CD8/FOXP3 ratioRatio < 1.6 in their residual tumors after neoadjuvant chemotherapyTheir Residual Tumors After Neoadjuvant Chemotherapy (NAC) that convertThat Convert to CD8/FOXP3 ratioRatio >= 1.6Time frame: Up to 21 days → 21 days
    Secondary outcomes 14 edited
    What changed in the outcomes
    • EditedChanges in vimentin expressionVimentin ExpressionTime frame: Up to 60 days → 60 days
    • EditedImpact of lengthLength of treatmentTreatmentTime frame: Up to 60 days → 60 days
    • ChangedBefore Incidence of adverse eventsNow Number of Patients Experiencing a Grade 3 or Greater of Adverse EventTime frame: Up to 60 days → 60 days
    • Editedother outcomeChanges in mitosesMitosesTime frame: Up to 60 days
    • Editedother outcomeChanges in nuclear pleomorphismNuclear PleomorphismTime frame: Up to 60 days
    • Editedother outcomeChanges in tubule formationTubule FormationTime frame: Up to 60 days
    • Editedother outcomeChanges in tumorTumor Ki-67Time frame: Up to 60 days
    • Editedother outcomeChanges in serum tyrosine kinase inhibitorSerum Tyrosine Kinase Inhibitor (TKI)Time frame: Up to 60 days
    • Editedother outcomeChanges in tumorTumor-infiltrating lymphocytesLymphocytesTime frame: Up to 60 days
    • Editedother outcomeEffect of abemaciclibAbemaciclib on tumor ribonucleic acidTumor Ribonucleic Acid (RNA)-sequencingSequencing (seqSeq) dataDataTime frame: Up to 60 days
    • Editedother outcomeEffect of abemaciclibAbemaciclib on the phenotypePhenotype of peripheral blood mononuclear cellsPeripheral Blood Mononuclear Cells (PBMC)Time frame: Up to 60 days
    • Editedother outcomeEffect of abemaciclibAbemaciclib on formalinFormalin-fixed paraffinParaffin-embedded (FFPE) tumor sectionsTumor SectionsTime frame: Up to 60 days
    • Editedother outcomeChange in in frequencyFrequency of JAK-2 amplificationsAmplificationsTime frame: Baseline up to time of surgery
    • Editedother outcomeChange in microbiome with exposureMicrobiome With Exposure to abemaciclibAbemaciclibTime frame: Baseline up to prior to surgery
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03979508
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Jan 10, 2020
Primary completion
Dec 26, 2024
Completion
Dec 26, 2024
Results posted
Nov 2, 2026
Last update
Nov 2, 2026

Study contacts

Matthew P. Goetz, M.D.
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion